Results 11 to 20 of about 29,411 (265)

Tolerating CD47

Clinical and Translational Medicine
AbstractCluster of differentiation 47 (CD47) occupies the outer membrane of human cells, where it binds to soluble and cell surface receptors on the same and other cells, sculpting their topography and resulting in a pleiotropic receptor‐multiligand interaction network.
Jeffrey S. Isenberg, Enrique Montero
openaire   +4 more sources

CD47 as a Potential Target to Therapy for Infectious Diseases

Antibodies, 2020
The integrin associated protein (CD47) is a widely and moderately expressed glycoprotein in all healthy cells. Cancer cells are known to induce increased CD47 expression.
Lamin B. Cham, Tom Adomati, Fanghui Li, Murtaza Ali, Karl S. Lang   +4 more
doaj   +2 more sources

CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis

Cells
CD47 is expressed on cell surfaces and acts as a “don’t eat me” signal by interacting with signal-regulatory protein-α on the macrophage surface. Some cancer cells express CD47 protein and can evade macrophage phagocytosis.
Yunmi Ko, Seog-Yun Park, Jong Woong Park, June Hyuk Kim, Hyun Guy Kang, Jun Ah Lee   +5 more
doaj   +2 more sources

Facilitating cholangiocarcinoma inhibition by targeting CD47

Experimental and Molecular Pathology
Immune evasion is one of the mechanisms by which cancer cells acquire immunity during cancer development and progression. One of these is the increased expression of cluster of differentiation 47 (CD47), a transmembrane glycoprotein that protects cells ...
Kulthida Vaeteewoottacharn, Sakda Waraasawapati, Phattarin Pothipan, Ryusho Kariya, Saowaluk Saisomboon, Supawadee Bunthot, Chawalit Pairojkul, Kanlayanee Sawanyawisuth, Kazuhiko Kuwahara, Sopit Wongkham, Seiji Okada   +10 more
doaj   +2 more sources

Human CD47 Expression Permits Survival of Porcine Cells in Immunodeficient Mice that Express SIRPα Capable of Binding to Human CD47

Cell Transplantation, 2011
Signal regulatory protein α (SIRPα) is a critical immune inhibitory receptor on macrophages, and its interaction with CD47 prevents autologous phagocytosis.
Chunfeng Wang, Hui Wang, Kentaro Ide, Yuantao Wang, Nico Van Rooijen, Hideki Ohdan, Yong-Guang Yang M.D., Ph.D.   +6 more
doaj   +2 more sources

Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma. [PDF]

Adv Sci (Weinh)
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Li J, Ying S, Zhang Y, Wang J, Wan Q, Gong L, Xu D, Yang Z, Lu H, Yin Y, Fang X, Pu Z.   +11 more
europepmc   +2 more sources

Targeting CD47 for cancer immunotherapy [PDF]

Journal of Hematology & Oncology, 2021
AbstractMuch progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic agents with 46 clinical trials in the NCT ...
Zhongxing Jiang, Hao Sun, Jifeng Yu, Wenzhi Tian, Yongping Song   +4 more
openaire   +3 more sources

CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. [PDF]

PLoS ONE, 2012
How do effector CD4 T cells escape cell death during the contraction of the immune response (IR) remain largely unknown. CD47, through interactions with thrombospondin-1 (TSP-1) and SIRP-α, is implicated in cell death and phagocytosis of malignant cells.
Vu Quang Van, Nobuyasu Baba, Manuel Rubio, Keiko Wakahara, Benoit Panzini, Carole Richard, Genevieve Soucy, Denis Franchimont, Genevieve Fortin, Ana Carolina Martinez Torres, Lauriane Cabon, Santos Susin, Marika Sarfati   +12 more
doaj   +1 more source

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

Frontiers in Drug Discovery, 2023
Cell surface molecules PD-L1 and CD47 are potent inhibitors of adaptive and innate anti-cancer immunity. We sought to generate a safe, therapeutic, bispecific antibody specifically targeting, and blocking both PD-L1 and CD47 inhibitory activity.
Irene Tang, Lauren Schwimmer, Shenda Gu, Wei Wei Prior, Hieu Van Tran, Allan Chan, Anna McClain, Christopher C. Fraser, Chunyan Sun, Meimei Si, Guijiang Wang, Yunxia Zhao, Ning Zhang, Jiayu Fu, Mengxin Liu, Chuanzeng Cao, Shihao Chen   +16 more
doaj   +1 more source

CD47-SIRPα checkpoint disruption in metastases requires tumor-targeting antibody for molecular and engineered macrophage therapies

, 2022
Data for the Cancers (2022) publication: CD47-SIRPα checkpoint disruption in metastases requires tumor-targeting antibody for molecular and engineered macrophage ...
Lawrence J. Dooling (12354141), Jason Andrechak (12240833), Dennis Discher (12354151), Brandon Hayes (12354143), Justine Lee (12354175), William Zhang (12354172), Michael Tobin (12086102), Xiaoling Jin (12354193), Jerome Irianto (12354148)   +8 more
core   +1 more source